Ayşe BATIREL, Mehmet Engin TEZCAN, Recep DEMİRHAN, Nurullah ESER, Ezgi KÖRLÜ

Pulse steroid treatment for hospitalized adults with COVID-19

Background/aim: High-dose steroid has been shown to reduce the mortality rate in Corona virus disease 2019 (COVID-19) patients who need oxygen support. Here, we evaluated the effectiveness of pulse-steroid in case of unresponsiveness to treatment with high dose steroid. Materials and methods: The study is a retrospective controlled trial. We divided the patients in 3 groups: standard-care therapy alone, highdose steroid treatment (6 mg/day dexamethasone equivalent), and pulse-steroid treatment (250 mg/day methyl-prednisolone). One hundred and fifty patients were enrolled in each group. All patients were hospitalized and needed oxygen support. We matched the patients according to disease severity at the onset of hypoxia, weight of co-morbidities, age, and sex. We then compared 3 groups in terms of mortality, length of hospitalization, need for intensive care unit (ICU) admission and mechanical ventilation (MV), length of stay in ICU, and duration of MV. Results: The pulse-steroid group had shorter ICU stay. The median ICU stay was 9.0 (CI 95% 6.0–12.0) days in standard-care group, 8.0 (CI 95% 5.0–13.0) days in high-dose steroid group and 4.5(CI %95 3.0–8.0) days in pulse-steroid group. Moreover, although patients in pulsesteroid group were initially unresponsive to high dose steroid therapy, they achieved similar results compared to the high-dose steroid group in other outcomes except for length of hospital stay. Conclusion: Pulse-steroid treatment would be an option for COVID-19 patients who do not respond to the initial high-dose steroid treatment.Key words: Coronavirus disease 2019, steroid treatment, mortality rate, intensive care unit stay

PDF

___

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity 2020; 109: 102433. doi: 10.1016/j.jaut.2020.102433
2. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Reviews: Cardiology 2020; 17: 259- 260. doi: 10.1038/s41569-020-0360-5
3. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, Behavior, and Immunity 2020. doi: 10.1016/j.bbi.2020.03.031
4. Pei G, Zhang Z, Peng J, Liu L, Zhang C et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. Journal of the American Society of Nephrology 2020. doi: 10.1681/ASN.2020030276
5. Hajifathalian K, Mahadev S, Schwartz RE, Shah S, Sampath K et al. SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant. World Journal of Gastroenterology 2020; 26: 1546-1553. doi: 10.3748/wjg.v26.i14.1546
6. Incidence of venous thromboembolism in hospitalized patients with COVID-19. Journal of Thrombosis and Haemostasis 2020. doi: 10.1111/jth.14888
7. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C et al. Estimates of the severity of coronavirus disease 2019: a modelbased analysis. Lancet Infectious Diseases 2020; 20: 669-677. doi: 10.1016/S1473-3099(20)30243-7
8. Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens RW et al. Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof). Mayo Clinic Proceedings 2020; 95: 1454-1466. doi: 10.1016/j.mayocp.2020.04.027
9. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS et al. Remdesivir for the treatment of Covid-19-final report. New England Journal of Medicine 2020; 383: 1813-1826. doi: 10.1056/NEJMoa2007764
10. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infectious Diseases 2020; 20: 1135-1140. doi: 10.1016/S1473- 3099(20)30434-5
11. Soy M, Keser G, Atagunduz P, Tabak F, Atagunduz I et al. Cytokine storm in COVID-19: pathogenesis and overview of antiinflammatory agents used in treatment. Clinical Rheumatology 2020; 39: 2085-2094. doi: 10.1007/s10067-020-05190-5
12. Group RC, Horby P, Lim WS, Emberson JR, Mafham M et al. Dexamethasone in hospitalized patients with Covid-19- preliminary report. New England Journal of Medicine 2020. doi: 10.1056/NEJMoa2021436
13. Sterne JAC, Murthy S, Diaz JV, Slutsky AS et al. Association between administration of systemic corticosteroids and mortality among critically ıll patients with COVID-19: a meta-analysis. The Journal of the American Medical Association 2020; 324: 1330- 1341. doi: 10.1001/jama.2020.17023
14. Yang Q, Liu Q, Xu H, Lu H, Liu S et al. Imaging of coronavirus disease 2019: a Chinese expert consensus statement. European Journal of Radiology 2020; 127: 109008. doi: 10.1016/j.ejrad.2020.109008
15. Smith GB, Redfern OC, Pimentel MA, Gerry S, Collins GS et al. The National early warning score 2 (NEWS2). Clinical Medicine (London) 2019; 19: 260. doi: 10.7861/clinmedicine.19-3-260
16. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods of Information in Medicine 1993; 32: 382-387.
17. Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062. doi: 10.1016/S0140-6736(20)30566-3
18. Sterne JAC, Diaz J, Villar J, Murthy S, Slutsky AS et al. Corticosteroid therapy for critically ill patients with COVID-19: a structured summary of a study protocol for a prospective metaanalysis of randomized trials. Trials 2020; 21: 734. doi: 10.1186/s13063-020-04641-3
19. Ruiz-Irastorza G, Pijoan JI, Bereciartua E, Dunder S, Dominguez J et al. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: an observational comparative study using routine care data. PloS One 2020; 15: e0239401. doi: 10.1371/journal.pone.0239401
20. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. European Respiratory Journal 2020; 56. doi: 10.1183/13993003.02808-2020
21. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. The Journal of the American Medical Association 2020; 324: 1307- 1316. doi: 10.1001/jama.2020.17021
22. Monreal E, Sainz de la Maza S, Natera-Villalba E, BeltranCorbellini A, Rodriguez-Jorge F et al. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases 2020. doi: 10.1007/s10096-020-04078-1
23. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clinical Immunology 2020; 215: 108427. doi: 10.1016/j.clim.2020.108427
24. Noone T. An overview of steroid use and its potential side-effects. Nursing Times 2006; 102: 24-27.
25. Fernandez-Cruz A, Ruiz-Antoran B, Munoz-Gomez A, SanchoLopez A, Mills-Sanchez P et al. A retrospective controlled cohort study of the ımpact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrobial Agents and Chemotherapy 2020; 64. doi: 10.1128/AAC.01168-20